John Hervert
Internal Medicine · Deland, FLNPI 1235428921
Payments from drug & device makers
Across 677 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$1K
- Amgen$1K
- Lilly USA, LLC$977
- Boehringer Ingelheim$636
- plus $4K from 48 others
What the payments were for
- Food & beverage$12,186100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,218 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 119 | $111,566 |
| OzempicSemaglutide | 42 | $74,019 |
| MounjaroTirzepatide | 44 | $58,918 |
| EliquisApixaban | 37 | $44,080 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $25,261 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $23,676 |
| JardianceEmpagliflozin | 14 | $22,123 |
| JanuviaSitagliptin Phosphate | 36 | $20,723 |
| EntrestoSacubitril/Valsartan | 21 | $20,122 |
| Repatha SyringeEvolocumab | 20 | $20,051 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $19,243 |
| XareltoRivaroxaban | 16 | $13,293 |
| Bydureon BciseExenatide Microspheres | 11 | $10,449 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,568 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,462 | $111,566119 claims |
| Novo NordiskOzempic | $2,143 | $74,01942 claims |
| Lilly USA, LLCMounjaro | $977 | $58,91844 claims |
| PfizerEliquis | $444 | $44,08037 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $308 | $42,91958 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $72 | $25,26125 claims |
| Boehringer IngelheimJardiance | $636 | $22,12314 claims |
| MerckJanuvia | $161 | $20,72336 claims |
| NovartisEntresto | $364 | $20,12221 claims |
| Johnson & JohnsonXarelto | $192 | $13,29316 claims |
| AbbVieSynthroid | $2,029 | $2,28127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Deland
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.